Compare · BOLT vs NVO
BOLT vs NVO
Side-by-side comparison of Bolt Biotherapeutics Inc. (BOLT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BOLT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $172.11B, about 13044.9x BOLT ($13.2M).
- BOLT has been more active in the news (10 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 6 for BOLT).
- Company
- Bolt Biotherapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- $38.90-1.38%
- Market cap
- $13.2M
- $172.11B
- 1M return
- -
- -0.41%
- 1Y return
- -
- -18.26%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 10
- 9
- Recent ratings
- 6
- 25
Bolt Biotherapeutics Inc.
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BOLT
- Large owner Coastlands Capital Lp bought $309,922 worth of shares (53,094 units at $5.84) (SEC Form 4)
- Bolt Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Bolt Biotherapeutics Inc.
- Large owner Coastlands Capital Lp bought $319,000 worth of shares (50,000 units at $6.38) (SEC Form 4)
- SEC Form 3 filed by Bolt Biotherapeutics Inc.
- SEC Form SCHEDULE 13G filed by Bolt Biotherapeutics Inc.
- Bolt Biotherapeutics to Participate in Upcoming Conferences
- SEC Form 4 filed by Bolt Biotherapeutics Inc.
- SEC Form 3 filed by Bolt Biotherapeutics Inc.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S